DeMONSTRATE-TB Study in Ethiopia
Recruiting
Phase 2
Phase 3
Interventional Study
Reducing Tuberculosis Incidence
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Sex
- Any
- Trial phase
- Phase 2/3
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 131,438 (estimated)
- Sponsor
- Management Sciences for Health · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Ending the TB epidemic by 2035 in Ethiopia would be possible if TB notification declines by an annual factor of at least 15% from the current notification rate of 132 per 100,000 population. This requires highly effective strategies to reduce TB transmission and maximize TB prevention among populations at risk of developing TB, such as Household contacts and people living with HIV.
The investigat…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Adults:
* Greater than or equal to 18 years old
* Provides consent
* Living in study site area (woreda)
2. Children
* Aged 12 to 17 years
* Living in the study site area (woreda)
* Assent to enrollment
* Guardian provides consent for enrollment
3. Young…
Contacts